Help Legalize Therapeutic Psilocybin in Canada


Help Legalize Therapeutic Psilocybin in Canada

Psilocybin-assisted psychotherapy is the professionally guided use of psilocybin (magic mushrooms) in combination with psychotherapy and differs greatly from the recreational use of psychedelics. This clinically tested treatment program encompasses careful medical oversight of the medicine session, as well as intention setting and integration psychotherapy sessions (without psilocybin) that help prepare an individual for lasting healing.

Psilocybin therapy for palliative care and treatment-resistant health conditions (treatment-resistant depression, post-traumatic stress disorder, substance use disorders, cluster headaches, etc..)  is a safe, compassionate, effective, and reasonable treatment option for Canadians in medical need that has been proven by rigorous clinical research studies and confirmed by real-world anecdotal evidence.

What problems are patients facing?

47 Canadians in medical need, supported by TheraPsil, have received approved section 56 exemptions allowing them to legally use, possess, and transport psilocybin in the context of psilocybin therapy. Unfortunately, there are many more Canadians, equally suffering who have been waiting months for a response from the Minister.

Section 56 exemptions, where the Minister of Health grants individual exemptions for psilocybin use to patients on a case-by-case basis, while beneficial to open the door to compassionate access over the past year, is not a sustainable model to offer healthcare. When some patients are approved for this treatment option, and others are not, it is clear: section 56 exemptions are arbitrary, discriminatory, and infringe upon patients section 7 and section 15 charter rights.

Health Canada dragging feet on approving magic mushrooms for therapeutic use, patients and advocates say

Health Canada dragging feet on approving magic mushrooms for therapeutic use, patients and advocates say

What is the solution?

Canada urgently needs a change in regulations that would allow medical psilocybin and psilocybin therapy to be accessible through consultation between a patient and their healthcare provider, not through case-by-case exemptions granted by the Federal Minister of Health.

In August 2021, TheraPsil, in consultation with patients, lawyers, and policy experts drafted a proposed framework for medical psilocybin in Canada.

Why demand medical regulations for psilocybin, now?

Allied Organizations

The following organizations agree that Canada is in urgent need of medical psilocybin regulations so that Canadians in medical need of psilocybin and psilocybin therapy can have safe, predictable, equal and compassionate access to this treatment option.


Take Action

Canadians are ready for regulatory change


On November 1st, 2021, TheraPsil sent Canada’s New Health Ministers, The Honourable Minister of Health, Jean-Yves Duclos, and Minister of Mental Health and Addictions Dr. Carolyn Bennett a letter co-signed by 194 Canadian healthcare professionals, ranging from psychiatrists, palliative care doctors, nurses, social workers and other diverse professionals, regarding the urgent need for medical psilocybin regulations in Canada.

Political Endorsements

Learn More

TheraPsil is hosting a 5-week webinar series, every other Wednesday at 4pm PST starting on October 20th 2021 where you can learn about psilocybin therapy and the urgent need for regulatory change, first-hand from patients, healthcare professionals, and advocates.

Therapsil in the News

Core Spore Supporters

Without the generosity of our supporters, our research, training, public education and advocacy wouldn’t be possible for Canadians seeking legal psilocybin-assisted psychotherapy. Thank you to the inspiring organizations and individuals who believe in TheraPsil to create and sustain an ethical psychedelics industry in Canada, our initiatives would not be possible without your support.







Want to sign up for our Newsletter to stay in the loop?